Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
The major development of the past decade in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the introduction of cetuximab in combination with platinum plus 5-fluorouracil chemotherapy (CT), followed by maintenance cetuximab (the “E...
Main Authors: | Athanassios Argiris, Kevin J. Harrington, Makoto Tahara, Jeltje Schulten, Pauline Chomette, Ana Ferreira Castro, Lisa Licitra |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fonc.2017.00072/full |
Similar Items
-
Editorial: Advances in the Systemic Therapy and Combined Modality Approaches for Head and Neck Cancer
by: Athanassios Argiris, et al.
Published: (2019-11-01) -
Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
by: Tomohiro Enokida, et al.
Published: (2018-08-01) -
Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck
by: Jacques Bernier
Published: (2011-12-01) -
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
by: Thomas Chevalier, et al.
Published: (2021-06-01) -
Cetuximab Plus Chemotherapy versus Chemotherapy Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
by: Lang Y, et al.
Published: (2020-11-01)